Kornimate/medical-research-clean huggingface dataset:
validity and reliability of the turkish version of the tele-pulmonary rehabilitation acceptance scale

Conditions: Pulmonary Disease; Telehealth; Pulmonary Rehabilitation

Summary: the objective of this research is to translate the tele-pulmonary rehabilitation acceptance scale into turkish and assess its reliability and accuracy.

the use of telehealth in pulmonary rehabilitation, also known as telerehabilitation, is a novel approach in healthcare practice. in order to effectively implement telerehabilitation programs, it is important to evaluate how potential users perceive and accept this new type of program. thus, the aim of this research was to create a measuring tool that could assess the level of acceptance of telerehabilitation among healthcare providers and patients. a group of experts in pulmonary rehabilitation, telehealth, information technology, and scale development have reviewed and confirmed the content validity of the tele-pulmonary rehabilitation acceptance scale. this scale is significant because it offers a consistent means of collecting data to measure the level of acceptance towards telerehabilitation among potential users. this study aims to translate and show the consistency and validity of the tele-pulmonary rehabilitation acceptance scale in turkish.

Eligibility criteria:
inclusion criteria: * being a patient in need of pulmonary rehabilitation or a healthcare professional working in the field of pulmonary rehabilitation. * being a native turkish speaker. * giving consent to participate in the study. exclusion criteria: * any disease or condition that prevents reading, understanding, or filling out forms. * not giving consent to participate in the study.
reinforced staple line on leak rate in distal pancreatectomy

Conditions: Pancreatic Neoplasms

Summary: the investigators propose a randomized, controlled trial of stapled pancreatic transection versus mesh reinforced stapled pancreatic transection. for the duration of the study period, participating surgeons will utilize a standardized staple technique. either a reabsorbable polytrimethylene carbonate mesh (seamguard®) or reabsorbable strips of bovine pericardium (peri-strips dry®) will be used to reinforce the stapled pancreatic transection line in the test group. in order to have a uniform test method, the investigators will utilize a laparoscopic stapling device for both open and laparoscopic procedures and a uniform staple size (4.8mm).

pancreatic leak remains a significant cause of morbidity and extra cost following distal pancreatectomy. historically, previous attempts to reduce the leak rate have met with limited success. to examine this problem the investigators propose a randomized, controlled trial of stapled pancreatic transection versus mesh reinforced stapled pancreatic transection. for the duration of the study period, participating surgeons will utilize a standardized staple technique. either a reabsorbable polytrimethylene carbonate mesh (seamguard®) or reabsorbable strips of bovine pericardium (peri-strips dry®) will be used to reinforce the stapled pancreatic transection line in the test group. in order to have a uniform test method, the investigators will utilize a laparoscopic stapling device for both open and laparoscopic procedures and a uniform staple size (4.8mm). a drain will be placed in the left upper quadrant at the time of resection. drainage of the pancreatic resection bed is widely accepted and remains our current standard of care.

Eligibility criteria:
inclusion criteria: * participants must be 18 years or older and able to give consent. any patient undergoing a distal pancreatectomy, laparoscopic or open, will be eligible for randomization. * no exclusion is provided for primary diagnosis. in the event of a patient undergoing a planned resection of another organ or organs with only a possibility of a distal pancreatic resection (i.e. colectomy, hepatectomy, gastrectomy, nephrectomy), the patient will still be eligible for inclusion in the study. we expect that some patients will be randomized but not resected (ie metastasis identified). a few patients may not be stapled using the study device for technical reasons (ie the stapler does not fit). the data will be analyzed in an intent-to-treatment approach. exclusion criteria: none specified

Keywords: pancreas adenocarcinoma precancerous lesions of the pancreas (mucinous cystic neoplasms, ipmn) pancreas neuroendocrine cancer
effect of maraviroc on metabolic function in obese subjects (phase i)

Conditions: Hypertriglyceridemia

Summary: the purpose of this study is to determine the effect of maraviroc therapy in obese insulin resistant subjects on: 1. plasma triglyceride concentration 2. plasma hdl-cholesterol and ldl-cholesterol concentrations 3. plasma markers of cardiometabolic risk and inflammation

the purpose of this study is to determine, in obese insulin resistant subjects, the effect of maraviroc therapy, a selective antagonist of the human chemokine receptor ccr5, on: 1. plasma triglyceride concentration 2. plasma hdl-cholesterol and ldl-cholesterol concentrations 3. plasma markers of cardiometabolic risk and inflammation

Eligibility criteria:
inclusion criteria: * obese (body mass index (bmi) between 30 and 45.9) * increased plasma triglyceride concentrations (150-400 mg/dl) exclusion criteria: * active or previous infection with hepatitis b or c * history of alcohol abuse * current alcohol consumption (\>20g/day) * severe hypertriglyceridemia (\>400 mg/dl) * active peptic ulcer disease * diabetes * pregnant or lactating * take statins, fibrates, niacin, moderate to strong cyp3a4 inhibitors or inducers, or any other medication that might confound interpretation of the study results will be excluded.

Keywords: hypertriglyceridemia triglyceride cholesterol maraviroc
clinical effects of intermitent continuous glucose monitoring in type 1 diabetes

Conditions: Type 1 Diabetes

Summary: observational cross-sectional multicenter study about clinical effect of intermitent continuous glucose monitoring (flash) in adult type 1 diabetes patients in an spanish public health system.

observational cross-sectional multicenter study about clinical effect of intermitent continuous glucose monitoring (flash) in adult type 1 diabetes patients in an spanish public health system. all clinical variables are gathered from chart review. data analysis is conducted using spss statistic software. results are presented as mean +/- sd values. a paired student´s t-test or wilconxon signed test were used fr the analysis differences. comparison between proportions were analyzed using a chi-square test. a p value \<0.05 was considered statistically significant. the protocolo was apporved by the reference castilla-la mancha public health service ethic commitee. all participants provided written consent.

Eligibility criteria:
inclusion criteria: * presence of type 1 diabetes. * age \>18 years. * patients previously followed in the diacam study. exclusion criteria: * any other kinds of diabetes.

Keywords: type 1 diabetes intermitent continous glucose monitoring flash
capecitabine as radiosensitising agent in neoadjuvant treatment of locally advanced resectable rectal cancer

Conditions: Resectable Rectal Cancer Clinical Stage II and III

Summary: a phase ii study aimed to evaluate the efficacy and toxicity of preoperative chemoradiotherapy with capecitabine in locally advanced resectable rectal cancer.

preoperative chemoradiation has become a standard part of treatment protocols in stage ii and iii rectal cancer. compared to postoperative chemoradiotherapy, the advantage of preoperative application of chemotherapeutics and irradiation includes improved compliance, reduced toxicity and downstaging of the tumour in a substantial number of patients. the latter may enhance the rate of curative surgery, permit sphincter preservation in patients with low-sited tumours and have a positive impact on the quality of life of these patients. orally administered capecitabine (xeloda®, hoffmann - la roche ltd, basel, switzerland) mimics the pharmacokinetics of continuous 5-fu infusion and makes chemoradiotherapy more patient-friendly. the mechanism of capecitabine activation, preferably in tumour cells, may further enhance its efficacy and tolerability, offering the potential for an enhanced therapeutic ratio.the aim of the present phase ii study was to evaluate the efficacy and toxicity of preoperative chemoradiotherapy with capecitabine in patients with locally advanced rectal cancer. the primary endpoint of the study is a pathologically determined complete remission rate (pcr) of the disease locally and regionally. secondly, the rate of sphincter preservation in low-sited tumours, overall downstaging rate,toxicity and survival parameters will be analysed.

Eligibility criteria:
inclusion criteria: * histologically verified adenocarcinoma of the rectum, * resectable clinical stage ii or iii (iucc tnm classification 2002); * no prior radiotherapy and/or chemotherapy; * world health organisation (who) performance status \< 2; * age at diagnosis of 18 or older; * and adequate bone marrow, liver, renal and cardiac function (no history of ischemic heart disease). exclusion criteria: * a history of prior malignancy other than non-melanoma skin cancer or in situ carcinoma of the cervix

Keywords: capecitabine chemoradiation rectal cancer phase ii study
blood loss and complications of internal fixation of femoral neck fractures in patients treated with clopidogrel

Conditions: Femoral Neck Fractures; Pertrochanteric Fractures; Antiaggregant Therapy

Summary: patients suffering from femoral neck or pertrochanteric fractures have a high rate of mortality and morbidity associated mainly with deconditioning and immobilization. surgical management including open reduction and internaql fixation has been shown to reduce complication and improve outcome in such patients. delay of surgery produces less optimal results and is associated with higher morbidity even after 24-48 hours of fracture event. patients treated with platelet antiaggregants are exposed to higher blood loss during surgery and related complications, as demonstrated in patients treated with aspirin. however, cessation of antiaggregant therapy before surgery may be associated with complications of a hypercoagulable state and surgery delay. clpopidogrel is a fairly new approved antiaggregant drug indicated in cases of failed aspirin treatment in ischemic heart disease and cerebrovascular disease patients as well as in primary prevention of stent restenosis. no data regarding complications of hip surgery in patients treated with clpopidogrel is available. study hypothesis: definitive surgical treatment of patients treated with clopidogrel undergoing open reduction and internal fixation of pertrochnteric and femoral neck fractures is safe although associated with more extensive blood loss during surgery and postoperative wound complications.


Eligibility criteria:
inclusion criteria: * age \> 60 * pertrochanteric or femoral neck fracture within 48 hours * clopidogrel treatment - study group * no antiaggregant treatment - control group * asa score \<=3 exclusion criteria: * hematologic malignancy * hematologic malfunction * warfarin treatment * previous active gi or other internal bleeding - within 1 year * thrombocytopenia \< 150

Keywords: femoral neck fractures pertrochanteric fractures antiaggregant therapy clopidogrel plavix
rheumatoid foot insole

Conditions: Rheumatoid Arthritis

Summary: the present study aims to evaluate the effect of insoles for foot arthritis.

a randomized, controlled, double-blind, prospective trial being conducted involving 80 patients with rheumatoid arthritis, according to american college of rheumatology (acr) criteria, and foot pain, selected from outpatient clinics - federal university of sao paulo (unifesp). patients will be randomized in to two groups: experimental (40) and control (40). the experimental group will use ethyl-vinyl acetate (eva) foot orthoses, with support retrocapital and support of medial arch (insole intervention). the control group will use the same material flat insole (insole placebo).

Eligibility criteria:
inclusion criteria: * patients with established diagnosis ra according to criteria of the american college of rheumatology (acr) functional classes i, ii and iii * foot pain with vas between 3 - 8 cm for walking * age 18-65 years * basic medication stable for at least three months * not made infiltrations in feet and ankles in the last three months and not during the study * agreed to participate and signed term of informed consent exclusion criteria: * other musculoskeletal disorders in symptomatic lower limbs * diseases of the central and peripheral nervous system * decompensated diabetes mellitus * no walking * rigid deformities in the feet * use of insoles in the last three months * surgery scheduled in the next 12 months * allergy to the material * mental deficiency

Keywords: rheumatoid foot foot pain insoles foot function electronic baropodometer plantar pressure gait analysis
the effectiveness of ai molar mind for smoking cessation through dental health evaluation

Conditions: Smoking Cessation; Tobacco Dependence

Summary: smoking cessation remains a significant public health challenge, with millions of individuals struggling to quit despite available interventions.

oral health deterioration is a well-documented consequence of smoking, including periodontal disease, tooth discoloration, and oral cancer. recent advancements in artificial intelligence (ai) have led to the development of ai molar mind, a digital tool designed to assess oral health and provide personalized feedback to motivate behavioral change. this study aims to evaluate the efficacy of ai molar mind in aiding smoking cessation by leveraging oral health evaluations as a motivational tool.

Eligibility criteria:
inclusion criteria: * adults aged 18-65 years * smoke ≥5 cigarettes per day * motivated to quit smoking, * have access to a smartphone or computer exclusion criteria: * pregnant women * individuals with severe psychiatric conditions * those already using other smoking cessation therapies.

Keywords: smoking cessation oral health
study of aminolevulinic acid to enhance visualization and resection of malignant glial tumors of the brain

Conditions: Brain Tumors

Summary: tumors of the central nervous system are potentially curable. for tumors of comparable histology and grade, resectability is the most important prognostic factor affecting survival particularly in children. however, the infiltrative nature of the malignant cells produces indistinct borders between normal and malignant tissues, and the lack of easily identifiable tumor margins confounds attempts toward total resection. the investigators propose to identify the borders of tumors intraoperatively using protoporphyrin fluorescence of the malignant cells and thereby provide more complete tumor resection.


Eligibility criteria:
inclusion criteria: * patients must have clinically documented primary brain tumor for which resection is clinically indicated. anticipated histology at resection should include:anaplastic astrocytoma, astrocytoma malignant nos,brain stem glioma, ependymoma malignant, glioblastoma, glioblastoma multiforme, gliosarcoma, malignant oligodendroglioma, medulloblastoma, mixed astrocytoma-ependymoma * prior therapy is not a consideration in protocol entry * age unrestricted * ecog performance status\ 60%,) * life expectancy is not a consideration for protocol entry * patients must have normal organ and marrow function as defined below: * leukocytes _\> 3,000/ml * absolute neutrophil count _\>1,500/ml * platelets \>_100,000/ml * total bilirubin:within normal institutional limits * ast (sgot)/alt (sgpt) _\<2.5 x institutional upper limit of normal * creatinine:within normal institutional limits or creatinine clearance \>_60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal * women of child-bearing potential and men must agree to use adequate contraception(hormonal or barrier method of birth control;abstinence) prior to study entry and for the duration of study participation. * ability to understand and the willingness to sign a written informed consent document or have a parent or guardian with the ability to understand and the willingness to sign a written informed consent. exclusion criteria: * prior therapy is not an exclusion criterion * patients may not be receiving any other investigational agents history of allergic reactions attributed to compounds of similar chemical or biologic composition to aminolevulinic adic (ala) * personal or family history of porphyrias * uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * pregnant women are excluded, breastfeeding should be discontinued if mother is treated with aminolevulinic acid.

Keywords: malignant glial brain tumors
effects of inflattable cervical traction collar as compared to manual tracion in the management of cervical radiculopathy

Conditions: Cervical Radiculopathy

Summary: this study is a randomized control trial and the purpose of this study is to determine the effects of inflatable cervical traction collar as compared to manual traction in the management of cervical radiculopathy.

the purpose of this study is to determine the effects of inflatable cervical traction collar as compared to manual traction in the management of cervical radiculopathy on 1. pain 2. functional disability 3. range of motion data collection procedure: participants of interest would be approached and explained about the research. informed written consent will be taken. recruited participants will be allocated to either of the groups through a sealed opaque envelope method.

Eligibility criteria:
inclusion criteria: adults aged 19-44 years neck pain \>4 and \<8 on nprs ndi scoring \<24(moderate disability) positive spurling test positive distraction test active and passive rom limited/painful towards the side of pain radiating symptoms numbness/paresthesia radiating to upper limb both genders positive - upper limb neural tension tests (ulntt) will be included. - exclusion criteria: patients having bilateral radiating sign and symptoms cervical myelopathy cervical syringomyelia rheumatoid arthritis thoracic outlet syndrome brachial plexopathy cervical rib vertebrobasilar insufficiency recent history of fracture, surgery, trauma or whiplash positive alar ligament stress test positive sharp purser stress test cervical instability cancer, tumor or sudden weight loss. -
using novel imaging to more safely treat neuroendocrine tumors

Conditions: Neuroendocrine Tumors; Somatostatin Receptor-positive Neuroendocrine Tumor

Summary: the goal of this research is to determine if detectnettm pet/ct can be used to make lutathera therapy safer for patients with neuroendocrine cancer. participants will: * complete two phases involving 6 visits * undergo additional research pet/ct, and possibly spect/ct scans

the goal of this research study is to determine if detectnettm pet/ct scanning over several days can be used to deliver lutathera in a safer manner. in this research, participants will be asked to complete a screening phase and possibly a dosimetry phase. the screening phase will require 2 visits. the dosimetry phase will also require 3 research visits.

Eligibility criteria:
inclusion criteria: * candidates for 177lu-dotatate (lutathera) treatment for somatostatin receptor-positive neuroendocrine tumor exclusion criteria: * unable to lie flat during or tolerate pet/ct or spect/ct * known incompatibility to ct. spect, or pet scans * unlikely to comply with study procedures, restrictions and requirements and judged by the investigator that the participant is not suitable for participation in the study

Keywords: neuroendocrine tumors
double blind placebo controlled dose ranging study of the efficacy and safety of ssr149744c 300 or 600 mg for the conversion of atrial fibrillation / flutter

Conditions: Atrial Fibrillation; Atrial Flutter

Summary: double blind study to assess versus placebo the efficacy of ssr149744c for the conversion of atrial fibrillation/flutter to sinus rhythm at the time of the planned electrical cardioversion.

this is a dose ranging multicenter, multinational, randomized, double blind, placebo controlled, parallel arm study. patients with af/afl will be randomized to one of two doses of ssr149744c. the efficacy of ssr149744c will be based on the proportion of patients converting to normal sinus rhythm at the end of the treatment period (48 hours post first dose). patients will receive the study drug on d1 and d2. patients not converting pharmacologically to sinus rhythm will undergo an electrical cardioversion on d3.

Eligibility criteria:
inclusion criteria: * af/afl for \>72 hours and documented by 2 12-lead ecgs separated by at least 72 hours and indication for electrical cardioversion of the current af/afl episode as judged by the investigator. exclusion criteria: main criteria (non-exhaustive list): * women of childbearing potential without adequate birthcontrol, pregnant women, breastfeeding women, conditions which increase the risk of severe antiarrhythmic drug side effects, permanent pacemaker, permanent af/afl, contraindication to anticoagulant, severe left ventricular dysfunction, severe associated conditions.

Keywords: atrial fibrillation atrial flutter electric countershock
targeting the right ventricle in pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: this study is looking to see if giving ranolazine to subjects on stable pulmonary hypertension specific therapies but with right ventricular dysfunction (rvef \<45%) would improve their outcome. this study is accompanied by a baseline comparison of the metabolic profiling/microrna/ips cells of subjects with and without right ventricular dysfunction.


Eligibility criteria:
inclusion criteria: * symptomatic pulmonary hypertension based on one of the following criteria: idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary hypertension associated with connective tissue disease, chronic thromboembolic pulmonary hypertension-nonsurgical/distal vessel disease or patients who are reluctant to go to surgery within a 6-month period and are willing to participate, simple congenital such as repaired atrial septal defect or ventricular septal defect or unrepaired small atrial septal defect or ventricular septal defect with persistent and out of proportion pulmonary arterial hypertension, group 3 patients who have a component of pulmonary arterial hypertension, pulmonary arterial hypertension caused by conditions affect the veins and small vessels of the lungs, sickle cell disease, group 5 pulmonary hypertension such as polycythemia vera, essential thrombocythemia, sarcoidosis, or vasculitis, or metabolic disorder. * who functional class ii, iii, or iv * mean pulmonary artery pressure \>25 mmhg at rest * pulmonary capillary wedge pressure or left ventricular end diastolic pressure \< 15 mmhg * baseline 6-minute walk test distance \> 50 meters * stable on baseline existing ph specific therapy for 12 weeks with no dosage change within 28 days prior to screening. exclusion criteria: * previous treatment with or prior sensitivity to ranolazine * any family history of corrected qt interval prolongation, congenital long qt syndrome, or receiving drugs that prolong the corrected qt interval * parenchymal lung disease showing total lung capacity \< 50% of predicted or forced expiratory volume at one second/forced vital capacity \< 50% * portal hypertension associated with liver disease * left sided heart disease including any of the following: moderate or greater aortic or mitral valve disease, any left ventricle cardiomyopathy, left ventricular systolic dysfunction defined as an ejection fraction \< 50%, symptomatic coronary artery disease * uncontrolled hypertension * uncontrolled diabetes

Keywords: pulmonary hypertension right ventricular function ranolazine